Raul R. Rodriguez - 26 Jan 2023 Form 4 Insider Report for RIGEL PHARMACEUTICALS INC (RIGL)

Role: CEO, President, Director
Signature: /s/ Raymond Furey (Attorney-in-Fact)
Issuer symbol: RIGL
Transactions as of: 26 Jan 2023
Net transactions value: -$35,595
Form type: 4
Filing time: 07 Feb 2023, 15:30:24 UTC
Previous filing: 30 Dec 2022
Next filing: 25 Jan 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RIGL	Common Stock	Award	$0	+300,000	+21%	$0.000000	1,701,053	26 Jan 2023	Direct	F1, F2
transaction	RIGL	Common Stock	Sale	$35,595	-20,340	-1.2%	$1.75	1,680,713	06 Feb 2023	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RIGL	Employee Stock Option (right to buy)	Award	$0	+600,000		$0.000000	600,000	26 Jan 2023	Common Stock	600,000	$1.87	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest annually over four (4) years from February 1, 2023, with the first annual vest occurring on February 1, 2024.
F2	Includes 9,277 shares acquired under the Issuer's stock purchase plan.
F3	These shares were sold to cover tax withholding due upon vesting of Restricted Stock Units. Such "sales to cover" were automatically effected to satisfy tax withholding obligations and do not represent a discretionary trade by the Reporting Person.
F4	The shares of common stock subject to the option vest monthly over four (4) years from the vesting commencement date of January 1, 2023, subject to the Reporting Person's continuous service to the issuer through each such period.